Rani Therapeutics Holdings, Inc. Stock Price, News & Analysis

Rani Therapeutics (Nasdaq: RANI) initiated a Phase 1 clinical trial on Jan 8, 2026 to evaluate RT-114, an oral RaniPill® capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed by ProGen, for the treatment of obesity.

The single- and multiple-dose study will assess safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics including weight-loss signals versus subcutaneous injection. Preclinical RT-114 data showed oral delivery with bioavailability, PK, and weight-loss comparable to subcutaneous dosing. ProGen previously reported preclinical and early clinical glucose-lowering and weight-loss signals for PG-102 at EASD 2025.

Rani Therapeutics (Nasdaq: RANI) announced that its management team will participate in the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 8:45 am ET in Coral Gables, FL.

Presenters include CEO Talat Imran and CFO Svai Sanford in a fireside chat and 1x1 meetings. Investors can watch a live webcast via the company Investor Relations website and access a replay after the presentation.

Rani Therapeutics (Nasdaq: RANI) reported Q3 2025 results and a corporate update on Nov 6, 2025.

Key items: a Collaboration & License Agreement with Chugai potentially worth up to $1.085 billion; an oversubscribed $60.3 million private placement closed in October 2025; appointment of Abraham Bassan and Vasudev Bailey, Ph.D. to the board; presentation of preclinical data showing oral semaglutide via RaniPill® with comparable bioavailability to subcutaneous dosing; and a plan to initiate a Phase 1 trial of RT-114 by end of 2025. Financials: cash, cash equivalents and marketable securities were $4.1 million as of Sept 30, 2025 (vs. $27.6 million at Dec 31, 2024); Q3 R&D was $3.2 million, G&A $4.0 million, and net loss $7.9 million (vs. $12.7 million in Q3 2024). The company expects funds from the private placement and Chugai deal to support operations into 2028.

Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.

The abstract reports that oral semaglutide in dogs was bioequivalent to subcutaneous injections and produced similar weight loss. The poster (No. 647) will be presented by Kyle Horlen, DVM, VP of Nonclinical Development, on November 6, 2025, 2:30–3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1; the meeting is Nov 4–7, 2025 and includes virtual participation.

Rani Therapeutics (Nasdaq: RANI) announced on October 23, 2025 the appointments of Abraham “Abe” Bassan and Vasudev Bailey, Ph.D., to its Board of Directors and the departures of Andrew Farquharson and Maulik Nanavaty.

The company highlighted strategic value from its clinical-stage pipeline and a recent collaboration with Chugai. Rani also closed a previously announced private placement expected to raise approximately $60.3 million, led by Samsara BioCapital with participation from Anomaly, RA Capital, Invus, Special Situations Funds and executive chairman Mir Imran.

Rani Therapeutics (Nasdaq: RANI) closed an oversubscribed private placement on October 23, 2025, raising $60.3 million in gross proceeds via at-the-market pricing under Nasdaq rules.

The financing included issuance of 42,633,337 shares at $0.48 and pre-funded warrants for up to 82,366,667 shares at $0.4799, plus accompanying warrants exercisable upon stockholder approval to purchase up to 125,000,004 shares at $0.48 (5-year term). Samsara led the round; Samsara and Anomaly each gain the right to designate a board member. The company says net proceeds, a $10.0M upfront payment and an expected $18.0M milestone are expected to fund operations into 2028 and support the RaniPill platform.

Rani Therapeutics (Nasdaq: RANI) priced an oversubscribed private placement expected to raise approximately $60.3 million in gross proceeds, with closing targeted on or about October 21, 2025. The financing includes 42,633,337 shares at $0.48 each and pre-funded warrants for up to 82,366,667 shares at $0.4799 each, plus accompanying warrants to purchase up to 125,000,004 shares exercisable upon stockholder approval.

The company said net proceeds, together with a $10.0 million upfront payment and an expected $18.0 million technology-transfer milestone from a Chugai collaboration, are expected to fund operations into 2028. Samsara and Anomaly will each gain the right to designate a board member; Avenue converted $6.0 million of debt into equity as part of the transaction.

Rani Therapeutics (Nasdaq: RANI) announced a Collaboration and License Agreement with Chugai on October 17, 2025 to develop an oral product using RaniPill and a Chugai rare‑disease antibody.

Key terms: $10 million upfront, up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones, single‑digit royalties, and an option for Chugai to add up to five additional targets — bringing total potential deal value to $1.085 billion. Rani also announced an oversubscribed $60.3 million PIPE led by Samsara BioCapital; net proceeds plus upfront and an expected $18.0 million technology transfer milestone are expected to fund operations into 2028.

Rani Therapeutics (NASDAQ:RANI) reported Q2 2025 financial results and corporate updates. The company announced a strategic research collaboration with Chugai for two undisclosed molecules and presented promising preclinical data for RT-114, their novel oral bispecific GLP-1/GLP-2 receptor agonist for obesity treatment.

Financial highlights include a $4.3 million warrant inducement transaction and a $3.0 million registered direct offering. Cash position stood at $10.2 million as of June 30, 2025, down from $27.6 million at year-end 2024. The company reported a reduced net loss of $11.2 million compared to $13.4 million in Q2 2024, with decreased R&D and G&A expenses.

Rani plans to initiate a Phase 1 clinical trial for RT-114 in obesity treatment during H2 2025.